Trial reportNeuro-oncology2026
The impact of hearing loss on cognitive outcomes among children treated with radiation therapy for ependymoma.
Trial report in Neuro-oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00187226 (A Phase II Study of Image-Guided Radiation Therapy for Pediatric CNS Tumors and Quantification of Radiation-Related CNS Effects), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase II Study of Image-Guided Radiation Therapy for Pediatric CNS Tumors and Quantification of Radiation-Related CNS Effects
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundSensorineural hearing loss (SNHL) is a common adverse treatment effect among pediatric brain tumor survivors. Neurocognitive functioning among children for whom radiation therapy (RT) is the primary SNHL risk factor has received limited attention. Accordingly, this study investigated neurocognitive outcomes as a function of SNHL among children treated for ependymoma with RT.
methodsProspective, serial, neurocognitive, and audiology assessments were conducted with 145 children diagnosed with ependymoma and enrolled on a Phase II trial of conformal photon RT (NCT00187226; 53% female; 83% White; mean age at RT = 5.04 ± 4.47 years). SNHL was dichotomized as normal/mild-to-moderate or severe (Chang grade <2b vs. ≥2b). Cognitive risk was assessed for participants with severe SNHL in either ear who completed neurocognitive assessments at least one year after hearing loss (n = 50).
resultsAt pre-RT baseline, full scale IQ (FSIQ), verbal learning, and communication were lower than normative expectations (P < .05), with a significant decline in FSIQ, estimated IQ (EIQ), reading, and communication over time. FSIQ and communication skills were worse among children with severe SNHL across all time points (P < .05). EIQ showed greater decline over time in those with severe SNHL (P < .0005), even after accounting for age at RT and pre-RT chemotherapy.
conclusionsSevere SNHL was associated with worse intellectual functioning and communication skills across time points among pediatric ependymoma survivors. The decline in EIQ suggests increased risk related specifically to hearing loss. Severe SNHL following RT for ependymoma, even if only in 1 ear, is a cognitive risk factor requiring monitoring and intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.